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This article reports successful eradication of isolated cutaneous mucormycosis in a young poorly controlled type 1 diabetic 
patient with end-stage renal disease using a combination of systemic antifungal agents and aggressive surgical debridement.
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Introduction
Mucormycosis is a rare life-threatening opportunistic infection 
caused by environmentally acquired fungi found in soil and 
decaying vegetation.1 Diseases caused by fungi of the order 
Mucorales are mainly encountered in immunocompromised 
patients.2 Among poorly controlled diabetic patients, specifically 
those who are in a persistent ketoacidotic state, rhinocerebral 
mucormycosis is the most common and devastating form of 
disease and often presents a rapidly progressive aggressive 
course. Ketone reductase, the enzyme present in Rhizopus 
organisms, allows for rapid growth in a high-glucose, acidotic 
environment.3 Other manifestations of disease include 
pulmonary, gastrointestinal, cutaneous and disseminated 
mucormycosis.4 Cutaneous mucormycosis is almost always 
associated with disruption of the dermis by trauma or wounds 
and direct inoculation of spores resulting in rapidly progressive 
locally invasive disease into the subcutaneous tissue, fascia, 
muscle and bone.1 The angio-invasive nature of mucormycosis 
may also result in disseminated disease due to haematogenous 
spread. Of the different forms of mucormycosis, cutaneous 
mucormycosis has the lowest mortality rate (15%) and most 
favourable outcome.1 Early recognition, expeditious surgical 
debridement, antifungal treatment and management of 
predisposing conditions is imperative to prevent disseminated 
disease and improve survival.1 Most of the available literature 
supports the use of high-dose intravenous liposomal 
amphotericin-B (LAmB) as monotherapy and to date there have 
been no definitive guidelines regarding the use of systemic 
antifungal agents in cutaneous mucormycosis.5 However, a few 
case studies have reported promising outcomes with 
combination antifungal therapy.6 We report successful 
eradication of isolated cutaneous mucormycosis using a 
combination of systemic antifungal agents and aggressive 
surgical debridement.
Case report
A 21-year-old Caucasian female known to have poorly controlled 
type 1 diabetes mellitus diagnosed at age 2 and complicated by 
proliferative diabetic retinopathy, peripheral neuropathy, 
autonomic dysfunction and diabetic nephropathy presented 
with a history of allegedly sustaining a spider bite on her back 
one week prior to presentation. At presentation she also 
complained of headaches, backache, fever, dysuria and nausea. 
In the months leading to her presentation her physician had 
regularly attended her with regard to her poor glycaemic control 
and progressively worsening renal function. She had also been 
started on antihypertensive agents in January 2014.
At presentation her fasting blood sugar was 21 mmol/l. She had 
a wide anion gap metabolic acidosis due to renal impairment 
and sepsis, but no ketones were present on urine examination. 
She was haemodynamically stable. An area of well-demarcated 
necrotic tissue was present on her right flank at the site of the 
spider bite. A large erythematous area surrounded this (Figure 1). 
The patient and her family stated that the lesion progressed 
rapidly over a period of five days. On clinical suspicion of a 
necrotising process, surgical debridement was done immediately. 
Histopathological examination revealed broad aseptate hyphae, 
which branched at 90 degrees with Periodic Acid-Schiff (PAS) 
stain and fungal spores as well as foci of angioinvasion involving 
the deep dermis and subcutaneous tissue. These features were 
indicative of the presence of Mucor Spp (Figure 2). Tissue was 
also sent for fungal culture, but yielded no growth. The patient 
had, however, been on a broad-spectrum antibiotic for several 
days at the time of biopsy, which could have affected the culture 
yield.
In conjunction with the histopathologist and microbiologist a 
diagnosis of mucormycosis was made based on the typical 
histopathological features and appropriate clinical scenario. She 
was treated with an initial course of intravenous LAmB (5 mg/kg 
daily) in combination with intravenous caspofungin (70 mg on 
day one, followed by 50  mg daily) and aggressive repeated 
surgical debridement at days 23, 35 and 51 of intravenous LAmB 
therapy. A nephrologist was consulted prior to initiation of 
intravenous LAmB and caspofungin and the decision was made 
to start haemodialysis immediately in view of the presence of 
intractable metabolic acidosis, hyperkalaemia and oliguria. A 
number of tunnelled dialysis catheters were placed during her 
stay. Placement of a long-term dialysis catheter was delayed until 
confirmation of eradication of the cutaneous mucormycosis. The 
caspofungin was limited to a fourteen-day course. Daily Actisorb® 
silver 220 dressings were applied.
A decision was made to continue intravenous LAmB until the 
culture at the time of debridement showed no fungal growth. 
This resulted in a total of 56 days of intravenous LAmB (a cumulative 
dose of 16.8  g). A long-term dialysis catheter was inserted in 
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the right subclavian vein after eradication of the mucormycosis. 
She was discharged at day 56. She is currently receiving 
haemodialysis as an out-patient. Wound care was also done on 
an out-patient basis. There was excellent clinical resolution and 
regular cultures obtained from the wound site at follow-up visits 
showed no fungal growth. Secondary wound closure was done 
after two months of oral posaconazole therapy.
Discussion
Mucormycosis is a relatively uncommon yet aggressive 
saprophytic opportunistic infection.2 Clinical data are indicative 
that patients with phagocytic dysfunction are mostly at risk.1 
Phagocytes eliminate the hyphae and spores via oxygen-
dependent and oxygen-independent mechanisms. Patient 
populations mostly affected are immunocompromised individuals 
such as diabetics, particularly those with ketoacidosis, patients 
with haematological malignancies, and those undergoing 
haemopoietic and solid organ transplantation.1 Other risk factors 
include iron overload, treatment with iron chelators, trauma, 
burns, malnutrition and intravenous drug abuse.3 The prevalence 
of mucormycosis is low in patients with AIDS, suggesting that 
neutrophils, but not necessarily T lymphocytes, play a role in the 
defence against fungal spores.7 It has, however, infrequently been 
reported in immune-competent patients.3
The incidence of mucormycosis has increased over the past 
20 years. This is most likely due to the fact that the population at 
risk for the development of mucormycosis is growing steadily.1 
Cutaneous mucormycosis occurs through direct inoculation of 
spores into damaged dermal barriers. It has been reported after 
surgical procedures, placement of intravenous catheters, tattoos, 
traumatic injuries, insect bites and burns. In our patient the site of 
entry was believed to be a spider bite.1 It usually presents as an 
indurated area of cellulitis and rapidly progresses to an area of 
necrotic tissue due to ischaemia and tissue infarction as a result of 
the angioinvasive nature of the fungal hyphae. Although rarely 
encountered, cutaneous mucormycosis may lead to disseminated 
disease if not treated promptly.8 The rapidly progressive course, 
poor glycaemic control and persistent acidotic state placed 
mucormycosis very high on our list of differential diagnoses. The 
diagnosis of mucormycosis is based on the histopathological 
demonstration of broad, aseptate hyphae that branch at right 
angles and the presence of angiolymphatic invasion resulting in 
tissue necrosis and infarction. Fungal cultures of specimens 
confirm the diagnosis. Some 70–80% of cases of mucormycosis 
are caused by Mucor, Rhizopus and Lichtheimia species of the 
order Mucorales.2
After correct identification of mucormycosis at histological 
examination, a thorough review of the available literature was 
undertaken to determine the best combination of systemic 
antifungal agents to use in conjunction with extensive surgical 
debridement and correction of underlying metabolic 
abnormalities in view of a possible favourable outcome with early 
aggressive management strategies in isolated cutaneous 
mucormycosis.9 In the absence of clear guidelines regarding 
antifungal pharmacotherapy intravenous LAmB was chosen with 
caspofungin as adjunctive therapy. This decision was based on 
the following deciding factors: high-dose amphotericin B remains 
the drug of choice for mucormycosis.6,10 The lipid formulation was 
chosen in view of the patient’s poor renal function. Ibrahim et al. 
demonstrated a potential benefit of echinocandins in the 
treatment of Rhizopus oryzae, the most common cause of 
zygomycosis.11 A standard 14-day course of caspofungin was 




Figure 1: (a) A well-demarcated necrotic lesion on the right flank 
surrounded by an area of induration and erythema as captured 72 h 
after initial insult. (b) Lesion after second debridement showing signs 
of wound healing. However, hyphae still present on histopathological 
evaluation. (c) Wound demonstrating adequate granulation at eight 
weeks post-debridement.
Figure 2: (a) Histological section stained with PAS highlights cell wall 
of mucormycosis within the tissue biopsy with necrosis of the tissue 
and degenerate inflammatory cells surrounding the hyphae (400x 
magnification).
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persistent presence of typical hyphae on histopathological 
examination. After no fungal elements were demonstrated at the 
time of final debridement on day 51 and fungal cultures were 
negative, the azole posaconazole was commenced and 
intravenous therapy discontinued on day 56. Oral posaconazole 
(400  mg daily) was given for 12  weeks. Although no clear 
guidelines exist regarding the use of posaconazole as step-down 
therapy in cutaneous mucormycosis, we based the duration of 
therapy on a retrospective study by Van Burik et al. reporting a 
60% success rate when using posaconazole for 12  weeks in a 
patient with zygomycosis refractory to or intolerant of other 
antifungal agents.1
We conclude that the chosen combination of intravenous 
polyene-caspofungin therapy and aggressive surgical debridement 
followed by a further 12 weeks of oral posaconazole as step-down 
therapy successfully eradicated the cutaneous mucormycosis in 
our patient. Despite successful eradication we acknowledge the 
cost implications of this regimen. This is of particular concern in a 
resource-limited setting.
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